Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia

Br J Haematol. 2003 Jul;122(1):161-3. doi: 10.1046/j.1365-2141.2003.04395_3.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibiotics, Antineoplastic / administration & dosage*
  • Daunorubicin / administration & dosage*
  • Dose-Response Relationship, Drug
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Liposomes
  • Middle Aged
  • Ventricular Function, Left / drug effects

Substances

  • Antibiotics, Antineoplastic
  • Liposomes
  • Daunorubicin